Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.32 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GPR3 | P46089 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24152142 | 0.92 | PDPK1 (0.33) | MAPTRAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL24153009 | 0.91 | PDPK1 (0.32) | PDPK1CYP1A2 | |
| SCHEMBL24154474 | 0.90 | PIM3 (0.32) | PDPK1 | |
| SCHEMBL24151855 | 0.89 | KDM4E (0.33) | MAPTRAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL24151849 | 0.88 | KDM4E (0.33) | PDPK1CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL19831890 | 0.87 | MAPT (0.34) | MAPTRAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL15857587 | 0.86 | — | — | |
| SCHEMBL24152550 | 0.85 | MCL1 (0.32) | MAPTRAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL25660307 | 0.85 | MAPT (0.35) | MAPTRAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL10014532 | 0.85 | ATM (0.41) | MAPTRAB9ASMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713291-B2 | Compound for organic electronic device, organic electronic device using same, and electronic apparatus thereof | DUK SAN NEOLUX CO., LTD. (KR) | 2023-08-01 | — | — | US | disclosed |
| US-20190185411-A1 | COMPOUND FOR ORGANIC ELECTRONIC DEVICE, ORGANIC ELECTRONIC DEVICE USING SAME, AND ELECTRONIC APPARATUS THEREOF | DUK SAN NEOLUX CO., LTD. (KR) | 2019-06-20 | — | — | US | disclosed |
| US-20190131543-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING SAME, AND ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO., LTD. (KR) | 2019-05-02 | — | — | US | disclosed |
| WO-2017200320-A1 | COMPOUND FOR ORGANIC ELECTRONIC DEVICE, ORGANIC ELECTRONIC DEVICE USING SAME, AND ELECTRONIC APPARATUS THEREOF | 덕산네오룩스 주식회사 | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185411-A1 | COMPOUND FOR ORGANIC ELECTRONIC DEVICE, ORGANIC ELECTRONIC DEVICE USING SAME, AND ELECTRONIC APPARATUS THEREOF | PIEZO1, ORAI2, EXOC1 | MAPT 943/4885RAB9A 978/4885SMN1; SMN2 1473/4885 |
| US-11713291-B2 | Compound for organic electronic device, organic electronic device using same, and electronic apparatus thereof | PIEZO1, ORAI2, EXOC1 | MAPT 943/4885RAB9A 978/4885SMN1; SMN2 1473/4885 |
| US-20190131543-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING SAME, AND ELECTRONIC DEVICE THEREOF | ORC3, PIEZO1, ORAI2 | MAPT 426/4885RAB9A 1478/4885SMN1; SMN2 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.